

## DAFTAR PUSTAKA

- Al-Saadi, A.A. and Beierwaltes, W.H., 1966. Chromosomal changes in rat thyroid cells during iodine depletion and repletion. *Cancer research*, 26 (4 Part 1) : 676-688.
- Ameziane-El-Hassani, R., Talbot, M., Dos Santos, M.C.D.S., Al Ghuzlan, A., Hartl, D., Bidart, J.M., De Deken, X., Miot, F., Diallo, I., de Vathaire, F. and Schlumberger, M., 2015. NADPH oxidase DUOX1 promotes long-term persistence of oxidative stress after an exposure to irradiation. *Proceedings of the National Academy of Sciences*, 112(16) : 5051-5056.
- Boltze, C., Brabant, G., Dralle, H., Gerlach, R., Roessner, A. and Hoang-Vu, C., 2002. Radiation-induced thyroid carcinogenesis as a function of time and dietary iodine supply: an in vivo model of tumorigenesis in the rat. *Endocrinology*, 143(7) : 2584-2592.
- Cabanillas ME, McFadden DG dan Durante C. Thyroid cancer. *Lancet*. 2016. 38(10061): 2783-2795
- Cardoso, L.C., Martins, D.C., Figueiredo, M.D., Rosenthal, D., Vaisman, M., Violante, A.H. and Carvalho, D.P., 2001. Ca<sup>2+</sup>/nicotinamide adenine dinucleotide phosphate-dependent H<sub>2</sub>O<sub>2</sub> generation is inhibited by iodide in human thyroids. *The Journal of Clinical Endocrinology & Metabolism*, 86(9): 4339-4343.
- Cho YA, Kong SY, Shin A, Lee J, Lee EK, Kim J *et al*. Biomarkers of thyroid function and autoimmunity for predicting high-risk groups of thyroid cancer: a nested case-control study. *BMC Cancer*. 2014. 14(1): 873
- Cooper, D.S., Doherty, G.M., Haugen, B.R., Kloos, R.T., Lee, S.L., Mandel, S.J., Mazzaferri, E.L., McIver, B., Sherman, S.I. & Tuttle, R.M. (2006) Management guidelines for patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Taskforce. *Thyroid*. 16 (2) :109–142.

- Elbers LPB, Fliers E dan Cannegieter SC. The influence of thyroid function on the coagulation system and its clinical consequences. *J Thromb. Haemost.* 2018. 16(4): 634-645
- Ensley, J.F., Gutkind, S., Jacobs, J.A. and Lippman, S. (2003) Head and neck cancer: emerging perspectives. Gulf Professional Publishing.
- Evans, P.H.R., Montgomery, P.Q. and Gullane, P.J. (2009) Principles and Practice of Head and Neck Surgery and Oncology, Second Edition .CRC Press.
- Fiore, A.P.Z.P., Fuziwara, C.S. and Kimura, E.T., 2009. High iodine concentration attenuates RET/PTC3 oncogene activation in thyroid follicular cells. *Thyroid*, 19(11) : 1249-1256.
- Fiore, E., Rago, T., Provenziale, M.A., Scutari, M., Ugolini, C., Basolo, F., Di Coscio, G., Berti, P., Grasso, L., Elisei, R., Pinchera, A. and Vitti, P. (2009) Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: Thyroid autonomy may play a protective role. *Endocrine-Related Cancer*. 16 (4) :1251–1260.
- Fiore, M., Oliveri Conti, G., Caltabiano, R., Buffone, A., Zuccarello, P., Cormaci, L., Cannizzaro, M.A. and Ferrante, M., 2019. Role of emerging environmental risk factors in thyroid cancer: a brief review. *International Journal of Environmental Research and Public Health*, 16(7) : 1185.
- Gärtner, R., Rank, P. and Ander, B., 2010. The role of iodine and  $\delta$ -iodolactone in growth and apoptosis of malignant thyroid epithelial cells and breast cancer cells. *Hormones*, 9(1) : 60-66.
- Haugen, B.R., Alexander, E.K., Bible, K.C., Doherty, G.M., Mandel, S.J., Nikiforov, Y.E., Pacini, F., (2016) American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. *Thyroid*. 26 (1) : 1–133.

- Haymart, M.R., Repplinger, D.J., Levenson, G.E., Elson, D.F., Sippel, R.S., Jaume, J.C. & Chen, H. (2008) Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. *Journal of Clinical Endocrinology and Metabolism*. 93 (3) : 809–814.
- Haymart, M.R., Repplinger, D.J., Levenson, G.E., Elson, D.F., Sippel, R.S., Jaume, J.C. and Chen, H. (2008) Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. *Journal of Clinical Endocrinology and Metabolism*. 93 (3) : 809–814.
- Jonklaas J, Nsouli-Maktabi H, Soldin SJ. 2008. Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer. 18(9): 943-52.
- Jin S, Borkhuu O, Bao W dan Yang Y-t. Signaling pathway in thyroid cancer and their therapeutic implications. *J Clin Med Res*. 2016. 8(4): 284-296
- Kimura, E.T., Nikiforova, M.N., Zhu, Z., Knauf, J.A., Nikiforov, Y.E. and Fagin, J.A., 2003. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. *Cancer research*, 63(7):1454-1457.
- Kitahara, C.M. and Sosa, J.A., 2016. The changing incidence of thyroid cancer. *Nature Reviews Endocrinology*, 12(11): 646.
- Krohn, K., Maier, J. and Paschke, R., 2007. Mechanisms of disease: hydrogen peroxide, DNA damage and mutagenesis in the development of thyroid tumors. *Nature clinical practice Endocrinology & metabolism*, 3(10): 713-720.

- La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, et al. (2015) Thyroid cancer mortality and incidence: A global overview. *Int J Cancer*. 136(9):2187–95.
- Langer, R., Burzler, C., Bechtner, G. and Gärtner, R., 2003. Influence of iodide and iodolactones on thyroid apoptosis. *Experimental and clinical endocrinology & diabetes*, 111(06) : 325-329.
- Le, K.T., Sawicki, M.P., Wang, M.B., Hershman, J.M. & Leung, A.M. (2016) High Prevalence of Agent Orange Exposure Among Thyroid Cancer Patients in the National VA Healthcare System. *Endocrine Practice*. 22 (6): 699–702.
- Lebastchi, A.H. and Callender, G.G., 2014. Thyroid cancer. *Current problems in cancer*, 38(2): 48.
- Lee, G.A. and Umesh, M. (2011) Disorders of the Thyroid Gland. In: *CURRENT Diagnosis & Treatment Otolaryngology--Head and Neck Surgery, Third Edition* LANGE CURRENT Series 3th edition [online]. New York: Mcgraw-hill.: 571–591.
- Liu, X.H., Chen, G.G., Vlantis, A.C. and Van Hasselt, C.A., 2009. Iodine mediated mechanisms and thyroid carcinoma. *Critical reviews in clinical laboratory sciences*, 46(5-6): 302-318.
- Maier, J., Van Steeg, H., Van Oostrom, C., Paschke, R., Weiss, R.E. and Krohn, K., 2007. Iodine deficiency activates antioxidant genes and causes DNA damage in the thyroid gland of rats and mice. *Biochimica et Biophysica Acta (BBA)-Molecular Cell Research*, 1773(6):990-999.
- Mallya M dan Ogilvy-Stuart AL. Thyrotropic hormones. *Best Pract. Res. Clin. Endocrinol. Metab.* 2018. 32(1): 17-25
- McLeod, D.S.A., Watters, K.F., Carpenter, A.D., Ladenson, P.W., Cooper, D.S. and Ding, E.L. (2012) Thyrotropin and thyroid cancer diagnosis: A systematic review and dose-response meta-analysis. *Journal of Clinical Endocrinology and Metabolism*. 97 (8): 2682–2692.

- Mughal BB, Fini JB dan Demeneix BA. Thyroid-disrupting chemicals and brain development: an update. *Endocr Connect*. 2018. 7(4): R160-R186
- Myung-Chul L, Min JK, Choi HS, Cho SW, Lee GH, Park YJ *et al*. Postoperative thyroid-stimulating hormone levels did not affect recurrence after thyroid lobectomy in patients with papillary thyroid cancer. *Endocrinol Metab*. 2019. 34(2): 150-157
- Parura Y, Pontoh V dan Merung M. Pola kanker tiroid periode Juli 2013 – Juni 2016 di RSUP Prof. Dr. R. D Kandou Manado. *Jurnal e-Clinic*. 2016. 4(2): 1-6
- Rinaldi S, Plummer M, Biessy C, Tsilidis KK, Ostergaard JN, Overvad K *et al*. Thyroid-stimulating hormone, thyroglobulin, and thyroid hormones and risk of differentiated thyroid carcinoma: the EPIC study. *J Natl Cancer Inst*. 2014. 106(6): dju097
- Sasson M, Kay-Rivest E, Shoukrun R, Florea A, Hier M, Forest V *et al*. The T4/T3 quotient as a risk factor for differentiated thyroid cancer: a case control study. *J Otorhynol Head Neck Surg*. 2017. 46(28): 1-6
- Schlumberger, M., De Vathaire, F., Travagli, J.P., Vassal, G., Lemerle, J., Parmentier, C. and Tubiana, M., 1987. Differentiated thyroid carcinoma in childhood: long term follow-up of 72 patients. *The Journal of Clinical Endocrinology & Metabolism*, 65(6): 1088-1094.
- Sherwood L. *Fisiologi Manusia dari Sel ke Sistem*. 2016. Jakarta: Buku Kedokteran EGC
- Shi, Y., Zou, M., Schmidt, H., Juhasz, F., Stensky, V., Robb, D. and Farid, N.R., 1991. High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area. *Cancer Research*, 51(10): 2690-2693.
- Sorisky A. Subclinical hypothyroidism – what is responsible for its association with cardiovascular disease? *Rev Med Chill*. 2017. 145(12): 1579-1587

- Vitale, M., Di Matola, T., D'Ascoli, F., Salzano, S., Bogazzi, F., Fenzi, G., Martino, E. and Rossi, G., 2000. Iodide excess induces apoptosis in thyroid cells through a p53-independent mechanism involving oxidative stress. *Endocrinology*, 141(2): 598-605.
- Williams, D., 2008. Radiation carcinogenesis: lessons from Chernobyl. *Oncogene*, 27(2):S9-S18.
- Yeh, M.W., Bauer, A.J., Bernet, V.A., Ferris, R.L., Loevner, L.A., Mandel, S.J., Orloff, L.A., Randolph, G.W. & Steward, D.L. (2015) American Thyroid Association statement on preoperative imaging for thyroid cancer surgery. *Thyroid*. 25 (1): 3–14.
- Zhang, I., DeMauro-Jablonski, S. & Ferris, R.L. (2014) Treatment of Thyroid Neoplasm. In: *Bailey's Head and Neck Surgery: Otolaryngology*. [online]. Wolters Kluwer Health.: 2115–2129.
- Zimmermann, M.B. and Boelaert, K., 2015. Iodine deficiency and thyroid disorders. *The Lancet Diabetes & Endocrinology*, 3(4):86-29